NovAccess Global (OTCMKTS:XSNX) versus Roivant Sciences (NASDAQ:ROIV) Financial Review

Roivant Sciences (NASDAQ:ROIV) and NovAccess Global (OTCMKTS:XSNX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Roivant Sciences and NovAccess Global, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	0	2	7	1	2.90
NovAccess Global	0	0	0	0	0.00

Roivant Sciences currently has a consensus target price of $25.19, indicating a potential upside of 8.90%. Given Roivant Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe Roivant Sciences is more favorable than NovAccess Global.

Institutional and Insider Ownership

64.8% of Roivant Sciences shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 1.4% of NovAccess Global shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Roivant Sciences and NovAccess Global”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$29.05 million	553.76	-$171.98 million	($0.56)	-41.30
NovAccess Global	N/A	N/A	-$4.72 million	($0.11)	N/A

NovAccess Global has lower revenue, but higher earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than NovAccess Global, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Roivant Sciences has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, NovAccess Global has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500.

Profitability

This table compares Roivant Sciences and NovAccess Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-1,839.58%	-16.43%	-15.68%
NovAccess Global	N/A	N/A	N/A

Summary

Roivant Sciences beats NovAccess Global on 7 of the 13 factors compared between the two stocks.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

About NovAccess Global

NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient’s immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.